Targacept, Inc.

Other

Hall Labs LLC

Targaeept, Inc.

Jared Miller Wagner

Gary Maurice Dull

Balwinder Singh Bhatti

William Scott Caldwell

Srishailkumar Basawannappa Hadimani

Peter Anthony Crooks

Haeil Park

David R Hall

Dan Allen

Joshua Larsen

Jared Reynolds

Craig Harrison Miller

Jeffrey Daniel Schmitt

Merouane Bencherif

Terrece Pearman

Patrick Michael Lippiello

Michael B Consilvio

Stephen Scott Davis

Justin R Robinson

Kevin Cheatham

Grayland Page Dobson

Erin E Reich

Nathan Hopkins

Srishakumar Basawannappa Hadimani

A dryer for use with a bidet is disclosed. In one embodiment, a moveable dryer wand emits an air curtain as the dryer wand moves across the bidet bowl beneath the user after cleansing. We further disclose a dryer which produces a second air current which moves air in a different direction than that emitted by the dryer wand and further controls the movement of excess water remaining on a user after cleansing. A dryer that includes moveable dryer wand used in coordination with a moveable bidet wand are also disclosed and claimed herein.

Moving air curtain for toilet bidet dryer

A thin scale apparatus for measuring body weight includes 5 or more force sensors within a total thickness of between 0.4 inches and 0.004 inches measured between a bottom surface and a top surface of the thin scale apparatus. The thin scale is designed to be thin enough to be non-intrusive or not recognized by a user. A weight of a toilet user may be determined as a combination of additive force of force sensors in a thin scale and force sensor associated with a toilet seat of a toilet. The force sensors may be positioned in one or more cavities on a bottom side of a substrate material of the thin scale or be embedded within a substrate material. Embodiments of a standalone thin scale and a thin scale with a toilet are disclosed.

Thin weight scale

The present invention is directed to a toilet that includes a liquid level sensor on the surface of a flush jet fill tube. The liquid level sensor is a noncontact electrical impedance sensor that is an electrical capacitor. The capacitor may be used alone or with other volume sensors to detect volume of materials added to a toilet bowl. Some embodiments include a processor which records data and provides reports that may be clinically useful to assess the user's health status. The temporal nature of the liquid level sensor measurements is particularly useful because urination or defecation may be measured over time. Not only are total volumes detected but rates at which waste is deposited into the toilet during the entire excretion event are detected. These measurements are particularly useful in assessing certain health conditions.

Toilet with flush jet fill tube flow meter

Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.

Compounds capable of activating cholinergic receptors

Compounds Capable of Activating Cholinergic Receptors

The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.

Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryloxyalkylamines and arylthioalkylamines, including pyridyloxyl-alkylamines, phenoxyalkylamines, pyridylthiolalkylamines and phenylthio-alkylamines. Exemplary compounds include (2-(5-bromo(3-pyridylthio))-ethyl)methylamine, (2-(5-bromo(3-pyridylthio))isopropyl)methylamine, (2-(5-bromo(3-pyridylthio))propyl)methylamine, (3-(5-bromo(3-pyridylthio))-propyl)methylamine, 3-((3S)-3-pyrrolidinyloxy)pyridine, 3-(4-piperidinyloxy)pyridine, 3-(1-methyl-4-piperidinyloxy)pyridine, (3-benzo&lsqb;3,4-d&rsqb;1,3-dioxolan-5-yloxypropyl)methylamine, and methyl(3-tricyclo&lsqb;7.3.1.0<5,13>&rsqb;tridec-2-yloxypropyl)amine.

Pharmaceutical compositions and methods for use

Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryloxyalkylamines, including pyridyloxylalkylamines and phenoxyalkylamines. Exemplary compounds include dimethyl(2-(3-pyridyloxy)ethylamine, dimethyl(4-(3-pyridyloxy)butyl)amine, 2-(3-pyridyloxy)ethylamine, 4-(3-pyridyloxy)butylamine, methyl(3-(5-methoxy-3-pyridyloxy)propyl)amine, ethyl(3-(3-pyridyloxy)propyl)amine, methyl(2-(3-pyridyloxy)ethyl)amine, methyl(3-(6-methyl(3-pyridyloxy))propyl)amine, (3-(3-methoxyphenoxy)propyl)methylamine, (3-(5-chloro(3-pyridyloxy))-1-methylpropyl)methylamine, dimethyl(3-(3-pyridyloxy)propyl)amine, 3-(3-pyridyloxy)propylamine, methyl(4-(3-pyridyloxy)butyl)amine, 3-(5-chloro-3-pyridyloxy)propylamine, methyl(3-(5-isopropoxy-3-pyridyloxy)propyl)amine, (3-(5-chloro(3-pyridyloxy))propyl)methylamine, methyl(3-(5-(phenylmethoxy)(3-pyridyloxy))propyl)amine, methyl(3-(2-methyl(3-pyridyloxy))propyl)amine, (methylethyl)(3-(3-pyridyloxy)propyl)amine, benzyl(3-(3-pyridyloxy)propyl)amine, cyclopropyl(3-(3-pyridyloxy)-propyl)amine, methyl(1-methyl-3-(3-pyridyloxy)propyl)amine, methyl(3-(3-nitrophenoxy)propyl)amine, 1-(3-chloropropoxy)-3-nitrobenzene, (3-(3-aminophenoxy)propyl)methylamine, dimethyl(3-(3-(methylamino)-propoxy)phenyl)amine, methyl(3-tricyclo&lsqb;7.3.1.0<5,13>&rsqb;tridec-2-yloxypropyl)amine, (3-benzo&lsqb;3,4-d&rsqb;1,3-dioxolan-5-yloxypropyl)methylamine, 3-(4-piperidinyloxy)pyridine and 3-((3S)-3-pyrrolidinyloxy)pyridine.

Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryloxyalkylamines, including pyridyloxylalkylamines and phenoxyalkylamines, such as (3-(3-pyridyloxy)propyl)methylamine and (3-(5-bromo(3-pyridyloxy))propyl)methylamine.

Pharmaceutical compositions aryl substituted amine compounds, and in particular, 3-aminophenyl amine compounds are provided. Representative compounds are (4E)-N-methyl-5-(3-acetamido-4-methylphenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3-amino-4-methylphenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3-(dimethylamino)phenyl)-4-penten-2-amine, (4E)-N-methyl-5-(4-methyl-3-nitrophenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3-fluorophenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3,4-dichlorophenyl)-4-penten-2-amine and (4E)-N-methyl-5-(3,4-methylenedioxyphenyl)-4-penten-2-amine.

Pharmaceutical compositions aryl substituted amine compounds, and in particular, 3-aminophenyl amine compounds are provided. Representative compounds are (E)-4-(3-aminophenyl)-3-buten-1-amine, (E)-N-methyl-4-(3-aminophenyl)-3-buten-1-amine and (E)-N-methyl-5-(3-aminophenyl)-4-penten-2-amine.

Growing community of inventors

Durham, NC, United States of America

Jared Miller Wagner